Filing Analysis
TScan Therapeutics stockholders approved an amendment to double the company's authorized voting common stock from 300 million to 600 million shares. The vote occurred at the 2026 Annual Meeting, where shareholders also elected Class II directors and ratified the company's independent auditor.
🚩 Red Flags
- Doubling the authorized share capital from 300 million to 600 million shares creates a massive overhang and signals potential for significant future equity dilution.
📋 Key Facts
- Stockholders approved an amendment to increase authorized voting common stock from 300,000,000 to 600,000,000 shares.
- The Certificate of Amendment was filed and became effective on May 20, 2026.
- Katina Dorton and R. Keith Woods were elected as Class II directors.
- Deloitte & Touche LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
TScan Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The company reported financial results for the quarter ended March 31, 2026.
- The report was filed on May 6, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The press release containing the detailed financial data was furnished as Exhibit 99.1.
TScan Therapeutics announced the resignation of Leiden Dworak, Vice President of Finance and Principal Accounting Officer, effective April 10, 2026. The Company's current CFO, Jason A. Amello, will assume the additional role of Principal Accounting Officer.
📋 Key Facts
- Leiden Dworak notified the company of his resignation on March 31, 2026.
- The resignation is effective April 10, 2026.
- Jason A. Amello (CFO) is appointed as the Principal Accounting Officer effective April 10, 2026.
- The company stated there were no disagreements regarding operations, policies, or practices.
- Mr. Amello will receive no additional compensation for the added responsibilities.
TScan Therapeutics announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were released via a press release furnished with the filing.
📋 Key Facts
- Financial results cover Q4 2025 and the full fiscal year ended December 31, 2025.
- The press release is furnished as Exhibit 99.1.
- The report was signed by CEO Gavin MacBeath, Ph.D. on March 4, 2026.